more

AbbVie (ABBV)

(Delayed Data from NYSE)

$201.68 USD

+1.21 (0.60%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $200.01 -1.67 (-0.83%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Zacks News

Incyte (INCY) to Post Q2 Earnings: Will Jakafi Sales Disappoint?

by Zacks Equity Research Published on July 28,2021

Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports second-quarter 2021 results.

2 Blue Chip Stocks to Buy Before Earnings and Hold for Years

by Benjamin Rains Published on July 27,2021

Let's explore two blue chip stocks that investors might want to consider buying as they report Q2 earnings...

Is a Beat Likely for AbbVie (ABBV) This Earnings Season?

by Zacks Equity Research Published on July 27,2021

AbbVie's (ABBV) second-quarter results are expected to reflect the impact of strong demand for new drugs. Investors are likely to focus on any update related to guidance.

pharmaceuticals

Gilead (GILD) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research Published on July 27,2021

Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports second-quarter 2021 results.

Overstock.com (OSTK) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research Published on July 27,2021

Overstock.com's (OSTK) Q2 results are expected to reflect strength in expanding clientele and demand for online home furnishing. Stiff competition and cost escalations are overhangs.

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research Published on July 26,2021

AbbVie (ABBV) closed at $117.79 in the latest trading session, marking a -0.34% move from the prior day.

ABBVPositive Net Change

A Daily Drumbeat of Key Earnings: Global Week Ahead

by John Blank Published on July 26,2021

U.S. earnings are in full swing and investors will now watch tech heavyweights to gauge whether a recent shift away from the reflation trade and into big growth stocks that led markets for the last decade will continue.

earnings

What's in the Cards for AstraZeneca (AZN) in Q2 Earnings?

by Zacks Equity Research Published on July 26,2021

AstraZeneca's (AZN) second-quarter results are expected to reflect the impact of strong demand for new drugs. Investors are likely to focus on an updated guidance after Alexion acquisition.

pharmaceuticals

Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research Published on July 23,2021

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fiscal fourth-quarter results.

AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research Published on July 23,2021

AbbVie (ABBV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ABBVPositive Net Change

Why AbbVie (ABBV) Could Beat Earnings Estimates Again

by Zacks Equity Research Published on July 23,2021

AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

ABBVPositive Net Change

Pharma Stock Roundup: JNJ, NVS Q2 Earnings, PFE, ABBV, LLY & MRK FDA Updates

by Kinjel Shah Published on July 23,2021

J&J (JNJ) and Novartis (NVS) announce Q2 results. FDA delays decisions on JAK inhibitor drugs of Lilly (LLY), AbbVie (ABBV) and Pfizer (PFE) for eczema indication.

pharmaceuticals

Healthcare ETFs in Focus as Q2 Earnings Unfold

by Sweta Killa Published on July 22,2021

The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come.

etfs
medical

Roche's (RHHBY) 1H21 Sales Rise Despite Impact of Biosimilars

by Zacks Equity Research Published on July 22,2021

Roche's (RHHBY) performance in first-half 2021 was impressive on strong demand for new medicines and COVID-19 test kits. Impact of biosimilars continues to hurt sales.

Pfizer (PFE) Inks Vaccine Deal, Faces FDA Delay on JAK Drugs

by Zacks Equity Research Published on July 22,2021

Pfizer (PFE) partners with Biovac for manufacturing and distributing its COVID-19 vaccine in African Union. The FDA delays decision on Pfizer's regulatory filings for JAK inhibitors.

pharmaceuticals